Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 120-125 , March 2010

Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing

  • Katherine R. Gerrald, PharmD

      Affiliations

    • Wake Forest University Baptist Medical Center, Medical Center Boulevard, Pharmacy Department, Winston Salem, NC 27157, USA
    • ,
  • Dave L. Dixon, PharmD, BCPS, CDE, CPP

      Affiliations

    • Wake Forest University Baptist Medical Center, Medical Center Boulevard, Pharmacy Department, Winston Salem, NC 27157, USA
    • Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Debra J. Barnette, PharmD, BCPS, CDE, CPP

      Affiliations

    • Wake Forest University Baptist Medical Center, Medical Center Boulevard, Pharmacy Department, Winston Salem, NC 27157, USA
    • Wingate University School of Pharmacy, Wingate, NC, USA
    • ,
  • Virginia G. Williams, PharmD, BCPS, CDE, CPP

      Affiliations

    • Wake Forest University Baptist Medical Center, Medical Center Boulevard, Pharmacy Department, Winston Salem, NC 27157, USA
    • Wingate University School of Pharmacy, Wingate, NC, USA

Received 13 November 2009 ,Accepted 1 February 2010.

References 

  1. Lloyd-Jones D, Adams R, Carnethon M, et al. for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics—2009 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181
  2. Pedersen TR, Kjekshus J, Berg K, et al. for the Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  3. Shepherd J, Covve SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med. 1995;333:1301–1307
  4. Grundy SM, Cleeman JI, Merz CN, et al. for the Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–2497
  6. Waters DD, Brotons C, Chiang C-W, et al. for the Lipid Treatment Assessment Project 2 Investigators Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28–34
  7. Cross LB, Franks AS. Clinical outcomes associated with pharmacist involvement in patients with hyperlipidemia. Dis Manage Health Outcomes. 2005;13:31–42
  8. Straka RJ, Taheri R, Cooper SL, Smith JC. Achieving cholesterol target in a managed care organization (ACTION) trial. Pharmacotherapy. 2005;25:360–371
  9. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low-density lipoprotein goals. Pharmacotherapy. 2000;20:1375–1383
  10. Geber J, Parra D, Beckey NP, Korman L. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy. 2002;22:738–747
  11. O'Donnell DC, Chen N, Piziak VK. Goal attainment and maintenance of serum cholesterol level in a pharmacist-coordinated lipid clinic. Am J Health-Syst Pharm. 2001;58:325–330
  12. Till LT, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm. 2003;3:269–273
  13. Mazzolini TA, Irons BK, Schell EC, Seifert CF. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA medical centers. J Manag Care Pharm. 2005;11:763–771
  14. DiTusa L, Luzier A, Brady G, Reinhardt M, Snyder BD. A pharmacy-based approach to cholesterol management. Am J Manag Care. 2001;7:973–979
  15. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: hyperlipidemia. J Am Pharm Assoc. 2000;40:157–165
  16. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177–186
  17. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167:847–852
  18. Yilmaz MB, Pinar M, Naharci I, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther. 2005;19:437–440
  19. Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother. 2008;42:1195–1207
  20. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med. 2009;151:622–630
  21. Taylor J, Lopez L. Cholesterol: point-of-care testing. Ann Pharmacother. 2004;1252–1257
  22. Casalino LP, Dunham D, Chin MH, et al. Frequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med. 2009;169:1123–1129
  23. National Cholesterol Education Program Working Group on Lipoprotein Measurement. Recommendations on lipoprotein measurement. Washington, DC: US Department of Health and Human Services; 1995;NIH publication no. 65-3044
  24. Santee J. Accuracy and precision of the Cholestech LDX System in monitoring blood lipid levels. Am J Health-Syst Pharm. 2002;59:1774–1779
  25. Dale RA, Jensen LH, Krantz MJ. Comparison of two point-of-care lipid analyzers for use in global cardiovascular risk assessments. Ann Pharmacother. 2008;42:633–639

 Current address of Dr. Gerrald: University of North Carolina Hospital, Chapel Hill, NC.

PII: S1933-2874(10)00048-6

doi: 10.1016/j.jacl.2010.02.001

Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 120-125 , March 2010

Article Tools

* Image Usage & Resolution